GSA Class Deviation Takes Aim at Commercial Terms
Client Alert | 1 min read | 08.26.15
As reported by the Coalition of Government Procurement, GSA recently released a final version of the class deviation it previewed in March that purports to eliminate commercial terms that are inconsistent with federal law. Among other changes, the deviation (1) revises the order of precedence to give solicitation provisions precedence over commercial provisions; (2) rewrites commercial supplier agreement dispute resolution, automatic renewal, and audit right provisions; and (3) places limits on the use and applicability of click-wrap and other comparable commercial contract execution mechanisms.
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 8 min read | 01.27.25
Client Alert | 5 min read | 01.27.25
Client Alert | 2 min read | 01.27.25
State Department Pauses Almost All Foreign Assistance Funding
